As the FDA evaluates ecstasy treatment for PTSD, questions mount about the evidence

Clinical trials of MDMA have been promising, but concerns have emerged about the quality of the research. A June hearing scheduled by the Food and Drug Administration is likely to address them.


http://dlvr.it/T6qSMl